Overview
Matter Bio is a biotechnology research organization focused on the innovative preservation of genome integrity, with a mission to extend healthy human lifespans. The company centers its efforts on mitigating the impacts of aging by preventing and correcting genomic information loss. Operating as a longevity holding company, Matter Bio has established several subsidiaries dedicated to developing technologies for identifying and correcting disease-associated genomic changes. This privately held company is headquartered in New York City.
Recent Developments
On May 29, 2024, Matter Bio successfully completed a $7 million seed funding round, led by Lifespan Vision Ventures with notable contributions from quadraScope Ventures and support from the National Institutes of Health (NIH). These funds are targeted at advancing research into the information theory of aging, preparing for an Investigational New Drug (IND) application, and exploring groundbreaking genomic preservation technologies.
Key Personnel
- Christopher Bradley, CEO and Co-Founder: Bradley brings a robust blend of entrepreneurship and science, holding an adjunct professorship at NYU Tandon School of Engineering. He is a recognized speaker at major conferences, such as the Longevity Summit Dublin 2025.
- Sam Sharifi, PhD, Chief Scientific Officer and Co-Founder: Dr. Sharifi holds an impressive track record in biotechnology and aging research, with over ten years of experience in biogerontology.
- George Church, PhD: A prominent pioneer globally in genomics and synthetic biology, Dr. Church is a co-founder of the company, with a legacy of co-founding over 50 companies.
Scientific Focus and Innovation
Matter Bio's key scientific focus is on preserving DNA and genome integrity, addressing genomic alterations over time, such as mutations, structural variations, and epigenetic drift. The company applies an integrated approach, aiming to reverse or significantly mitigate aging drivers through its research capabilities.
Team and Expertise
With a strong workforce comprising over 30 top-tier scientists and clinicians, alongside seasoned executives, Matter Bio channels this collective expertise into developing breakthrough technologies focused on genomic stability and longevity therapeutics.
Market and Strategic Vision
Recognizing the burgeoning market for longevity and genome preservation technologies, Matter Bio is strategically positioned to capitalize on biotech sector innovations. Its strategic partnerships and visionary funding demonstrate a robust endorsement of its methodology and potential advancements.
Competitor Profiling
1. Vizgen
Vizgen is a biotechnology firm specializing in spatial genomics, based in Cambridge, Massachusetts. Founded in 2019, Vizgen has become a leader in single-cell spatial analysis with its MERSCOPE® platform. This platform combines advanced technologies like high-fidelity InSituPlex® assays and AI-driven STARVUE™ spatial image analysis, earning Vizgen the title of #1 private spatial biology company in 2024.
- Key Technologies: MERFISH and MERSCOPE®.
- Specialties: Translational research, multi-omics, transcriptomics, with applications in drug development and cancer research.
- Recent Developments: Merger with Ultivue to enhance spatial biology capabilities and expand multi-omics solutions.
- Corporate Activities: Partnerships, such as with Boudicca DX, to improve precision medicine tests.
2. Bright Peak Therapeutics
Operating from Basel, Switzerland, and San Diego, California, Bright Peak Therapeutics focuses on multifunctional precision immunotherapies for cancer and autoimmune diseases. Utilizing protein synthesis technology developed at ETH Zürich, it seeks to redefine standards of care with novel therapeutics.
- Key Products: BPT567, a bifunctional PD-1xIL-18 immunoconjugate undergoing trials.
- Key Collaborations: Versant Ventures' support with extensive protein engineering expertise.
- Leadership: Led by CEO Fredrik Wiklund, known for strategic growth in clinical development.
3. iECURE
Based in Pennsylvania, iECURE advances gene editing technologies primarily for liver disorders. Collaborating with the Gene Therapy Program (GTP) at the University of Pennsylvania, iECURE is focused on mutation-agnostic in vivo gene insertion therapies.
- Strategic Focus: Developing gene therapies to permanently insert healthy genes for correcting "loss of function" diseases.
- Key Leadership: CEO Joseph Truitt leads with a robust executive board.
- Funding and Growth: Launched with substantial capital, maintaining aggressive growth strategies.
4. Spark Therapeutics
A fully integrated gene therapy company in Philadelphia, Spark Therapeutics uses its adeno-associated viral (AAV) platform for treating inherited diseases. As a Roche center of excellence, it emphasizes transformative therapies.
- Key Facility: Gene Therapy Innovation Center in West Philadelphia.
- Platform Strengths: Expertise in AAV vector design for developing curative gene therapies.
5. WOODOO
A Paris-based materials technology company, WOODOO offers sustainable alternatives with potential applications in biotechnology. Known for transforming wood into high-performance materials, it aligns with sustainable development goals.
- Key Innovation: Augmented wood products with a 90% reduction in emissions.
- Growth and Market Penetration: Scaling within the global construction industry.
This competitor overview presents an analysis of Matter Bio's strategic positioning, technological innovation, and recent activities concerning its key competitors. The insights provide valuable groundwork for further strategic planning and market analysis.
